Tenecteplase vs. alteplase for acute ischemic stroke: a s

International Journal of Emergency Medicine 15, 1

DOI: 10.1186/s12245-021-00399-w

Citation Report

#	Article	IF	CITATIONS
1	Platelet-targeted thrombolysis for treatment of acute ischemic stroke. Blood Advances, 2023, 7, 561-574.	5.2	5
2	In Vitro Antithrombotic, Hematological Toxicity, and Inhibitor Studies of Protocatechuic, Isovanillic, and p-Hydroxybenzoic Acids from Maclura tricuspidata (Carr.) Bur. Molecules, 2022, 27, 3496.	3.8	7
3	Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review andÂmeta-analysis. Journal of Neurology, 2022, 269, 5262-5271.	3.6	20
4	Improving treatment for acute ischemic stroke—Clot busting innovation in the pipeline. Frontiers in Medical Technology, 0, 4, .	2.5	2
5	Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase. Stroke, 2022, 53, 3235-3237.	2.0	4
7	Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurology, The, 2023, 22, 117-126.	10.2	19
8	Lifetime economic potential of mobile stroke units in acute stroke care: A model-based analysis of the drivers of cost-effectiveness. Journal of Telemedicine and Telecare, 0, , 1357633X2211409.	2.7	1
9	Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials. Journal of the Neurological Sciences, 2023, 445, 120537.	0.6	7
10	Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis $\hat{a} \in A$ retrospective cohort analysis. IBRO Neuroscience Reports, 2023, 14, 353-357.	1.6	0
11	Terapi Tissue Plasminogen Activator untuk Stroke Iskemik Akut. , 2023, 50, 167-170.		O
12	Nanotechnology in Stroke: New Trails with Smaller Scales. Biomedicines, 2023, 11, 780.	3.2	1
13	Provision of drug and alcohol services amidst COVID-19 pandemic: a qualitative evaluation on the experiences of service providers. International Journal of Clinical Pharmacy, 2023, 45, 1098-1106.	2.1	2
14	Expanding Footprints of Biosimilar Tenecteplase. Annals of Indian Academy of Neurology, 2023, Publish Ahead of Print, .	0.5	0
15	Year in Review: Synopsis of Selected Articles in Neuroanesthesia and Neurocritical Care from 2022. Journal of Neuroanaesthesiology and Critical Care, 2023, 10, 003-011.	0.2	1
16	ST-elevation myocardial infarction after thrombolytic therapy with Tenecteplase for acute ischaemic stroke. BMJ Case Reports, 2023, 16, e252253.	0.5	1
17	Intravenous Thrombolysis in Acute Ischemic Stroke., 0, , .		O
18	Benefit–risk balance of fibrinolytic therapy in ST-elevation myocardial infarction as evaluated by physicians. European Journal of Emergency Medicine, 2023, 30, 216-218.	1.1	1
19	Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications. Annals of Emergency Medicine, 2023, 82, 720-728.	0.6	4

#	Article	IF	CITATIONS
20	Tenecteplase to Replace Alteplase? Comparing Thrombolytic Therapies for Acute Ischemic Stroke. Annals of Emergency Medicine, 2023, 81, 759-760.	0.6	1
21	Incidence of mechanical thrombectomy among stroke patients brought directly to a comprehensive stroke center versus transfer from a primary stroke center in upstate New York. Interventional Neuroradiology, 0, , 159101992311777.	1.1	0
22	The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator. Journal of Personalized Medicine, 2023, 13, 1175.	2.5	0
23	Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS). Expert Opinion on Drug Safety, 2024, 23, 221-229.	2.4	1
24	Hemiplegia in acute ischemic stroke: A comprehensive review of case studies and the role of intravenous thrombolysis and mechanical thrombectomy., 2024, 10, 59-68.		0
25	Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke. Expert Opinion on Drug Metabolism and Toxicology, 2024, 20, 25-36.	3.3	0
26	In silico study of combination thrombolytic therapy with alteplase and mutant pro-urokinase for fibrinolysis in ischemic stroke. Computers in Biology and Medicine, 2024, 171, 108141.	7.0	0
27	Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0